Achillion gains on HCV data

Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) gained $1.28 to $15.49 on Monday after it said 100% of patients receiving ACH-3102 plus Sovaldi sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD) achieved an SVR4 after six weeks of treatment in a Phase II trial.

Achillion said none of the study's 12 treatment-naive patients -- 10 with genotype 1a and two with 1b -- have relapsed to date. The company plans to present the study's SVR12 data next year. ...